Effects of thalassemia major and minor on bone density and skeletal development
DOI:
https://doi.org/10.33448/rsd-v13i11.47331Keywords:
beta-Thalassemia; Osteogenesis; Bone density.Abstract
The effects of thalassemia major and minor on bone density and skeletal development can have negative impacts on affected individuals when compared to the general population. It is therefore of interest to investigate the impact of these hematological disorders on bone density and skeletal development, and how these effects compare with each other and with healthy individuals. The aim of this article is therefore to present a systematic review of the effects of thalassemia major and minor on bone density and skeletal development. Initially, 11 articles were found in the Pubmed, Cochrane and BvSalud databases. Of these, we included articles that assessed patients with thalassemia major and minor, used methods to assess bone density and skeletal development, and compared the results with healthy individuals; and excluded studies that did not distinguish between thalassemia major and minor, did not use validated assessment techniques or did not present comparative data; a total of 5 articles were used. The studies reviewed point to a substantial impairment of bone formation and maintenance in individuals and animal models with thalassemia, showing that alterations in osteoblastic function and an increase in osteoclastic activity contribute to an imbalance in the bone remodeling process, although further studies are needed to clarify this.
References
Baldini, M., Forti, S., Marcon, A., Ulivieri, F. M., Orsatti, A., Tampieri, B., ... & Cappellini, M. D. (2010). Endocrine and bone disease in appropriately treated adult patients with beta-thalassemia major. Annals of Hematology, 89, 1207-1213.
Bonjour, J. P., Theintz, G., Buchs, B., Slosman, D., & Rizzoli, R. (1991). Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. The Journal of Clinical Endocrinology & Metabolism, 73(3), 555-563.
De Sanctis, V., Soliman, A. T., Elsefdy, H., Soliman, N., Bedair, E., Fiscina, B., & Kattamis, C. (2018). Bone disease in β thalassemia patients: past, present and future perspectives. Metabolism, 80, 66-79.
Doulgeraki, A., Athanasopoulou, H., Voskaki, I., Tzagaraki, A., Karabatsos, F., Fragodimitri, C., ... & Karagiorga, M. (2012). Bone health evaluation of children and adolescents with homozygous β-thalassemia: implications for practice. Journal of Pediatric Hematology/Oncology, 34(5), 344-348.
D’Eufemia, P., Finocchiaro, R., Celli, M., Raccio, I., Zambrano, A., Tetti, M., ... & Iacobini, M. (2010). Taurine deficiency in thalassemia major-induced osteoporosis treated with neridronate. Biomedicine & pharmacotherapy, 64(4), 271-274.
Estrela, C. (2018). Metodologia científica: ciência, ensino, pesquisa. Artes médicas.
Fucharoen, S., Ketvichit, P., Pootrakul, P., Siritanaratkul, N., Piankijagum, A., & Wasi, P. (2000). Clinical manifestation of β-thalassemia/hemoglobin E disease. Journal of Pediatric Hematology/Oncology, 22(6), 552-557.
Mahachoklertwattana, P., Chuansumrit, A., Sirisriro, R., Choubtum, L., Sriphrapradang, A., & Rajatanavin, R. (2003). Bone mineral density, biochemical and hormonal profiles in suboptimally treated children and adolescents with β‐thalassaemia disease. Clinical endocrinology, 58(3), 273-279.
Meloni, A., Pistoia, L., Ricchi, P., Putti, M. C., Gamberini, M. R., Cuccia, L., Messina, G., Massei, F., Facchini, E., Righi, R., Renne, S., Peritore, G., Positano, V., & Cademartiri, F. (2022). Link between Genotype and Multi-Organ Iron and Complications in Children with Transfusion-Dependent Thalassemia. Journal of personalized medicine, 12(3), 400.
Musallam, K. M., Barella, S., Origa, R., Ferrero, G. B., Lisi, R., Pasanisi, A., Longo, F., Gianesin, B., Forni, G. L., & Webthal® project (2024). Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years. Blood cells, molecules & diseases, 107, 102859.
Olivieri, N. F. (1999). The β-thalassemias. New England journal of medicine, 341(2), 99-109.
Otrock, Z. K., Azar, S. T., Shamseddeen, W. A., Habr, D., Inati, A., Koussa, S., ... & Taher, A. T. (2006). Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Annals of hematology, 85, 605-609.
Perrotta, S., Cappellini, M. D., Bertoldo, F., Servedio, V., Iolascon, G., D'agruma, L., ... & Iolascon, A. (2000). Osteoporosis in β‐thalassaemia major patients: analysis of the genetic background. British journal of haematology, 111(2), 461-466.
Pollak, R. D., Rachmilewitz, E., Blumenfeld, A., Idelson, M., & Goldfarb, A. W. (2000). Bone mineral metabolism in adults with β‐thalassaemia major and intermedia. British journal of haematology, 111(3), 902-907.
Rund, D., & Rachmilewitz, E. (2005). Beta-thalassemia. The New England journal of medicine, 353(11), 1135–1146.
Thongchote, K., Svasti, S., Sa-Ardrit, M., Krishnamra, N., Fucharoen, S., & Charoenphandhu, N. (2011). Impaired bone formation and osteopenia in heterozygous β IVSII-654 knockin thalassemic mice. Histochemistry and cell biology, 136, 47-56.
Vogiatzi, M. G., Autio, K. A., Mait, J. E., Schneider, R., Lesser, M., & Giardina, P. J. (2005). Low bone mineral density in adolescents with β‐thalassemia. Annals of the New York Academy of Sciences, 1054(1), 462-466.
Voskaridou, E., & Terpos, E. (2004). New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. British Journal of Haematology, 127(2), 127-139.
Voskaridou, E., Kyrtsonis, M. C., Terpos, E., Skordili, M., Theodoropoulos, I., Bergele, A., ... & Loukopoulos, D. (2001). Bone resorption is increased in young adults with thalassaemia major. British journal of haematology, 112(1), 36-41.
Voskaridou, E., Ntanasis-Stathopoulos, I., Christoulas, D., Sonnleitner, L., Papaefstathiou, A., Dimopoulou, M., ... & Terpos, E. (2019). Denosumab effects on serum levels of the bone morphogenetic proteins antagonist noggin in patients with transfusion-dependent thalassemia and osteoporosis. Hematology, 24(1), 318-324.
Voskaridou, E., Ntanasis-Stathopoulos, I., Papaefstathiou, A., Christoulas, D., Dimopoulou, M., Repa, K., ... & Terpos, E. (2018). Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial. Blood Advances, 2(21), 2837-2847.
Wonke. (1998). Bone disease in β‐thalassaemia major. British journal of haematology, 103(4), 897-901.
World Health Organization Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series 843. WHO, Geneva.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Renato Alves Nunes; Ana Laura Rezende Costa; Mariana Sanches de Carvalho; Marina Vilela Reis; Ray Braga Romero
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
